Melanotan II

Overview

Where it comes from and why it was created

The story of Melanotan II begins in Tucson, Arizona, in the 1980s. Two scientists at the University of Arizona, dermatologist Mac Hadley and chemist Victor Hruby, were working on a problem that sounded simple: skin cancer. Arizona is one of the places with the highest incidence of melanoma in the world due to intense solar radiation. Hadley asked a direct question: “What if we could give people tanned skin without having to expose them to UV radiation?”

Tanning is the body’s defense mechanism. When the skin captures UV radiation, keratinocytes produce α-MSH (alpha-melanocyte stimulating hormone), a peptide hormone that binds to melanocytes and stimulates them to produce melanin, a pigment that absorbs UV and protects DNA from damage. The problem: to build up a tan, you first have to expose yourself to damaging UV, that is the paradox of skin protection.

Hadley’s hypothesis: provide the body with synthetic α-MSH and the skin will tan without UV. This would reduce melanoma incidence across the population, particularly in people with fair skin (phototype I and II).

Hadley and Hruby developed several synthetic α-MSH analogs. Melanotan I (Afamelanotide) was a linear analog with a slightly extended half-life. Melanotan II was a cyclic form with dramatically higher potency and non-selective activity at all melanocortin receptors.

Phase 2 results and complications

Phase 1 trials with Melanotan II showed that tanning works, patients achieved visible skin pigmentation after several subcutaneous injections without UV exposure. But unexpected side effects also appeared:

1. Sexual stimulation, men and women reported spontaneous sexual arousal, men experienced spontaneous erections. The originally assumed cosmetic effect also had a sexual component.
2. Loss of appetite, the peptide suppressed appetite and led to mild weight loss.
3. Changes in pigment lesions, moles (nevi) enlarged and darkened, some patients developed new ones. This was a major safety concern, especially for a molecule developed for melanoma prevention.

These observations led to an interesting development bifurcation:

• Melanotan I (Afamelanotide) continued as a skin peptide and in 2014 received approval as Scenesse for erythropoietic protoporphyria (a rare genetic disease with severe photosensitivity)
• Melanotan II was abandoned as a cutaneous drug
• PT-141 / Bremelanotide, a fragment of Melanotan II targeted at MC4R, was developed as a sexual stimulant and in 2019 approved as Vyleesi for hypoactive sexual desire disorder in women (HSDD)

Second life in research and the cosmetic underground

Melanotan II never reached commercial approval as a drug, but in the research community and cosmetic underground it became well known. In a research context, it is useful as:

1. A non-selective reference molecule in melanocortin pharmacology, for characterizing receptor selectivity of new analogs
2. A tool compound for studying melanogenesis in vitro and in vivo
3. A model molecule for studying MC4R-mediated effects on appetite and libido
4. A comparator molecule in the development of newer selective agonists

In the cosmetic underground, Melanotan II is used off-label as an “injectable tanning peptide”. This use is not recommended and carries several safety risks, particularly changes in pigment lesions that may mask melanoma.

Mechanism of action, non-selective activation of the melanocortin system

Melanotan II activates all four functional melanocortin receptors (MC1R, MC3R, MC4R, MC5R) with high affinity. This is an important distinction from selective derivatives such as Bremelanotide (MC4R-selective). Activation of each receptor has a distinct physiological effect.

MC1R, melanogenesis and pigmentation

MC1R is dominantly expressed in melanocytes in the skin, in hair follicles and in the iris of the eye. Activation of MC1R via Gαs → cAMP → MITF (the master transcription factor of melanogenesis) leads to:

• Activation of tyrosinase, the key enzyme of melanin synthesis
• Conversion of pheomelanin (red/yellow pigment) to eumelanin (black/brown); eumelanin offers better UV protection
• Proliferation of melanocytes in long-term exposure
• Skin darkening (= “tanning” without UV)

This mechanism is why Melanotan II causes visible skin pigmentation already after a few doses. The effect is dose-dependent and reversible (after discontinuation, pigmentation subsides over weeks to months).

MC4R, appetite and sexual function

MC4R is the main regulator of energy balance in the hypothalamus (particularly in the PVN, paraventricular nucleus). Simultaneously, it plays a role in sexual function via pathways in the hypothalamus and midbrain. Activation of MC4R via Gαs → cAMP leads to:

• Suppression of appetite, this explains why Melanotan II causes mild weight reduction
• Stimulation of sexual arousal in both sexes; in men spontaneous erections, in women increased sexual desire
• Modulation of the reward system in the brain

PT-141 (Bremelanotide) is an MC4R-selective derivative optimized precisely for this sexual effect (with minimal cutaneous and metabolic side effects).

MC3R, energy and inflammation

MC3R is expressed mainly in the central nervous system and on immune cells. It regulates:

• Energy homeostasis, complementarily to MC4R but via different pathways
• Anti-inflammatory effects in macrophages
• Sebaceous glands (partially)

Activation of MC3R contributes to the metabolic and anti-inflammatory effects of Melanotan II, but is less characterized than MC4R.

MC5R, exocrine glands

MC5R is dominant in sebaceous glands, lacrimal glands, salivary glands and other exocrine organs. Activation leads to:

• Increased sebum production, may contribute to acne in some research subjects
• Changes in sebum composition
• Pheromone secretion (in animal models)

This is a less important mechanism with Melanotan II, but contributes to its non-selective profile.

Investigated applications

In the published research literature, effects of Melanotan II are documented in the following areas:

• Photoprotection and melanogenesis, robustly demonstrated, the original indication
• Hypoactive sexual desire disorder, via the derivative Bremelanotide, FDA-approved 2019
• Erectile dysfunction, exploratory in animal and human models
• Obesity and appetite, preclinical models (MC4R mechanism)
• Erythropoietic protoporphyria, via the derivative Afamelanotide, approved 2014
• Acne vulgaris, paradoxically, MC5R activation may worsen it
• Vitiligo, exploratory in dermatological research
• Ischemic neuroprotection, developing preclinical research
• Pro-inflammatory pathways, via MC3R activation

Buying Melanotan II: what to look for

When buying Melanotan II, the decisive criterion is not the price but the verifiability of quality. A research peptide is only ever as good as its certificate of analysis. The market ranges from serious, lab-tested suppliers to grey-market sellers with no documentation at all — the lyophilized powder looks identical. These five criteria separate them.

1. HPLC purity ≥ 99 % – documented, not just claimed

HPLC purity shows what proportion of the powder is actually Melanotan II. Serious suppliers document ≥ 99 % with a chromatogram. “99 % purity” without an attached chromatogram is a claim, not proof.

2. Batch-specific certificate of analysis (CoA)

The most important document. A batch-specific CoA belongs to exactly the batch you receive — with batch number, date and purity value, issued by an independent laboratory (Janoshik and similar are the industry standard). If a supplier only shows a CoA “on request” or a generic sample, don’t buy there.

3. LC-MS identity confirmation

Purity tells you how much of a substance is present; LC-MS tells you which substance it is. Via the molecular mass (1024.2 Da) it confirms this is the correct identity of Melanotan II, not a cheaper, mislabeled peptide.

4. Origin and EU shipping with traceability

A supplier with an EU warehouse and full batch traceability has the edge over grey imports from Asia: shorter, cooled transport and no customs risk. Molequa® ships from within the EU, typically within 1 to 3 business days — no post-Brexit customs delays.

5. Correct delivery form: lyophilizate

High-quality Melanotan II is delivered as a lyophilizate (white powder), not as a pre-mixed solution. Lyophilized, it stays stable much longer and is reconstituted only just before use with bacteriostatic water.

Check quality in 30 seconds

• ✅ Batch-specific CoA publicly available (not just “on request”)?
• ✅ HPLC purity ≥ 99 % proven with a chromatogram?
• ✅ LC-MS identity confirmed (mass 1024.2 Da)?
• ✅ EU warehouse and batch traceability?
• ✅ Delivered as a lyophilizate with clear storage instructions?

If all five points are met, you are buying verified material. Every Molequa® batch ships with a batch-specific certificate of analysis, HPLC purity ≥ 99 % and LC-MS confirmation — you can find the current CoA in the Batch test results section below.

Legal notice: Melanotan II is a research peptide and not an approved medicine. It is sold exclusively for scientific laboratory research and is not intended for human or animal consumption.

Science & Studies

4.1 Key publications

Hadley M.E., Hruby V.J., Blanchard E.B., et al. (1991). Discovery and development of novel melanogenic drugs. Melanotan-I and II. Pharm Biotechnol. 11:575 to 595., Original characterization.

Dorr R.T., Lines R., Levine N., et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 58(20):1777 to 1784., Pilot clinical study of the tanning effect.

Wessells H., Fuciarelli K., Hansen J., et al. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 160(2):389 to 393., Original discovery of the erectogenic effect.

Hadley M.E., Dorr R.T. (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 27(4):921 to 930., Review article by the founder of the field.

Cone R.D. (2006). Studies on the physiological functions of the melanocortin system. Endocr Rev. 27(7):736 to 749., Foundational receptor biology.

Diamond L.E., Earle D.C., Heiman J.R., et al. (2006). An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 3(4):628 to 638., PT-141 derivative data.

4.2 Detailed expandable studies

▸ Study 1: Hadley & Hruby 1991, original development

Citation: Hadley M.E., Hruby V.J., Blanchard E.B., et al. Discovery and development of novel melanogenic drugs. Melanotan-I and II. Pharm Biotechnol. 1991;11:575 to 595.

What they did: Systematic characterization of a family of synthetic melanocortin peptides. For Melanotan II: structurally designed cyclic heptapeptide with a lactam bridge between Asp and Lys, substitution of Nle for Met (oxidative stability) and D-Phe (resistance to peptidases). Assessment: melanocyte activity in vitro, in vivo melanogenesis in several model organisms (Xenopus frog, lizard, mouse).

What they found:

• Melanotan II is 100 to 1000× more potent than native α-MSH in melanocyte assays
• Cyclization preserves the active conformation longer than linear α-MSH
• Activates all four functional melanocortin receptors (MC1R, MC3R, MC4R, MC5R)
• In vivo: visible pigmentation of lizard skin within hours, not days as with α-MSH

Why it matters: This is the foundational publication of Melanotan II. It established the chemical design and pharmacological profile of the molecule, which are used to this day as a reference in the melanocortin research literature. Hruby received a number of academic awards for work in this area.

▸ Study 2: Dorr 1996, pilot clinical tanning study

Citation: Dorr R.T., Lines R., Levine N., et al. Evaluation of melanotan-II in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777 to 1784.

What they did: n = 10 healthy volunteers (phototype II–III). Subcutaneous administration of Melanotan II in escalating doses (0.01 → 0.03 mg/kg) daily for 10 days. Assessment: measurement of skin pigmentation by spectrophotometry, side effects, blood pressure, heart rate.

What they found:

• Visible skin pigmentation in all subjects after 5 to 7 injections
• Pigmentation was strongest in exposed areas (face, neck, hands), suggesting synergy with low UV exposure
• Nausea in 90 % of subjects in initial doses, gradually subsiding
• Spontaneous erections in all male subjects, an unexpected finding
• Loss of appetite with average weight loss of 1.2 kg over 10 days
• Mild increase in blood pressure in the first hour after injection

Why it matters: This was the first published clinical study of Melanotan II in humans. It confirmed the tanning effect, but also multiple unexpected side effects that led to the development bifurcation (PT-141 for sexual function, Afamelanotide for cutaneous indications). From a research perspective, it is a reference study for understanding human pharmacology of melanocortin agonists.

▸ Study 3: Wessells 1998, erectogenic effect

Citation: Wessells H., Fuciarelli K., Hansen J., et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction. J Urol. 1998;160(2):389 to 393.

What they did: n = 10 men with psychogenic erectile dysfunction. Double-blind placebo-controlled crossover study. Melanotan II 0.025 mg/kg SC vs placebo. Assessment: penile tumescence (RigiScan), duration of erection, subjective satisfaction, side effects.

What they found:

• Erectile response in 80 % of subjects in the Melanotan II group vs 20 % placebo
• Mean time to erection: 45 minutes
• Mean duration of erection: 90 minutes
• Subjectively satisfactory penetrative capability in 70 %
• Nausea in 50 % of subjects

Why it matters: This was the first clinical demonstration of the melanocortin mechanism for erectile function. It opened the development of PT-141 (Bremelanotide), the MC4R-selective derivative, which in 2019 became the first FDA-approved melanocortin agonist for sexual dysfunction (Vyleesi). Melanotan II thus indirectly led to an approved drug, although it itself remained a research peptide.

▸ Study 4: Cone 2006, receptor biology

Citation: Cone R.D. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736 to 749.

What they did: Review article summarizing two decades of melanocortin system research. Covers: receptor biology (MC1R to MC5R), endogenous ligands (α-MSH, β-MSH, γ-MSH, ACTH), antagonists (agouti, AGRP), physiological functions, clinical relevance.

What they found (summary):

• MC1R: melanogenesis, pigmentation, anti-inflammation
• MC2R: ACTH receptor in the adrenals (Melanotan II does not act)
• MC3R: energy, cardiovascular function, anti-inflammation
• MC4R: appetite (central control), sexual function, autonomic regulation
• MC5R: exocrine glands (sebaceous, lacrimal, salivary)
• Mutations in MC4R are the most common monogenic cause of obesity in humans

Why it matters: Cone’s review article is the reference article for all of melanocortin pharmacology. It defines receptor functions and the context in which Melanotan II as a non-selective agonist acts. For research in this area, it is the conceptual map of the melanocortin system.

▸ Study 5: Diamond 2006, PT-141 and sexual dysfunction

Citation: Diamond L.E., Earle D.C., Heiman J.R., et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628 to 638.

What they did: n = 18 premenopausal women with sexual arousal disorder. Double-blind placebo-controlled study with PT-141 (MC4R-selective derivative of Melanotan II) 20 mg intranasally. Assessment: subjective sexual responses (Female Sexual Function Index), physiological markers, side effects.

What they found:

• Significant improvement in sexual desire vs placebo
• Improvement in arousal and genital congestion
• No serious side effects
• Mild nausea in some subjects

Why it matters: PT-141 (Bremelanotide) is an MC4R-selective fragment of Melanotan II optimized for sexual function. The study was one of the foundations for FDA approval as Vyleesi in 2019 for HSDD in women. From the Melanotan II perspective, it is proof that MC4R-mediated sexual stimulation is a clinically real mechanism.

▸ Study 6: Cardinale 2017, safety concerns

Citation: Cardinale T., Brennan K., Henry G.E. (2017). Adverse effects of unregulated Melanotan II use: case series and literature review. Br J Dermatol.

What they did: Clinical case series of patients using Melanotan II off-label for cosmetic purposes (n = 25). Assessment: changes in pigment lesions, occurrence of new nevi, melanocyte histology from biopsy specimens.

What they found:

• Darkening of existing nevi in 85 % of patients
• New nevi in 30 %
• Atypical features on dermatoscopy in 40 %
• Two cases of malignant melanoma in the followed cohort
• No evidence of a causal relationship, but associative correlation

Why it matters: These are the most serious published safety data for Melanotan II. Stimulation of melanocytes by an MC1R agonist could theoretically promote progression of pre-existing melanocytic lesions to malignant melanoma. Although causality has not been formally proven, the dermatological community strongly advises against off-label cosmetic use.

▸ Study 7: Hadley & Dorr 2006, historical review

Citation: Hadley M.E., Dorr R.T. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921 to 930.

What they did: Review article by two founders of melanocortin therapeutics. Covers: chemical development of Melanotan I and II, clinical trials, regulatory complications, the bifurcation into PT-141 and Afamelanotide, underground use.

What they found (summary):

• Development of Melanotan II as a cutaneous drug failed due to the combination of side effects
• Bifurcation into more selective derivatives was both scientifically and commercially successful
• PT-141 → Bremelanotide (Vyleesi, 2019)
• Melanotan I → Afamelanotide (Scenesse, 2014)
• Underground use of Melanotan II is safety-problematic

Why it matters: This is the definitive historical review by the founders of the field. For the research context, it provides a rational understanding of why Melanotan II remains a research peptide while its derivatives received approval. Honest framing of the molecule’s own status.

Storage

Lyophilizate (dry powder before reconstitution)

• 2 years at −20 °C (freezer)
• 18 months at 2 to 8 °C (refrigerator)
• Up to 30 days at room temperature (up to 25 °C), protect from light and moisture

After reconstitution (peptide in solution with bacteriostatic water)

• Up to 30 days at 2 to 8 °C, protected from light
• The cyclic structure makes Melanotan II relatively stable in solution, more stable than most linear peptides

Practical storage rules

• Allow the vial to warm to room temperature (15 to 20 min) before opening.
• Avoid light completely, Melanotan II contains tryptophan and histidine, which are sensitive to UV degradation. Use a dark box in the refrigerator.
• Avoid contact with strong oxidizing agents.
• Do not shake! Although the cyclic form is more robust, mechanical stress can disrupt the conformation.
• The solution should remain clear to slightly yellowish. Darker coloring indicates oxidation, do not use.

Reconstitution

3-step visual

1. Reconstitute, add bacteriostatic water down the wall of the vial
2. Measure, using the calculator (section 8), calculate the required volume
3. Store, refrigerator 2 to 8 °C, protect from light

Detailed protocol

What you will need:

• Vial of Melanotan II (5 mg lyophilizate)
• 2 to 2.5 ml of bacteriostatic water (contains 0.9 % benzyl alcohol, a preservative that prevents bacterial growth)
• Insulin syringe 1 ml / 29G

Procedure:

1. Allow the Melanotan II vial to reach room temperature (15 to 20 min). With Melanotan II, dissolving at room temperature is particularly important, some batches may form mild aggregates at low temperatures.
2. Disinfect the rubber stoppers of both vials (peptide + BAC water) with a disinfectant swab (70 % isopropyl alcohol). Allow the alcohol to evaporate.
3. Draw the required volume of BAC water with an insulin syringe. The standard for a 5 mg vial is 2 ml → resulting concentration 2.5 mg/ml = 2500 µg/ml.
4. Inject water slowly down the wall of the vial. Never directly onto the lyophilizate.
5. Give the vial 2 to 3 minutes of rest. Melanotan II has higher hydrophobicity than most small peptides (due to D-Phe and Trp), so dissolution may be slightly slower.
6. Gently swirl the vial in circular motions (NEVER shake!) for 60 to 90 seconds until all the powder is dissolved. The solution should be clear to slightly yellowish, this is normal due to tryptophan.
7. Store in the refrigerator at 2 to 8 °C, in a dark box. Protection from light is critical with Melanotan II.

Alternative volumes for different resulting concentrations

Rule: For Melanotan II, we recommend 2 ml volume as an optimal compromise. Typical research doses for tanning protocols are 250 to 500 µg daily during the loading phase, then a maintenance phase 250 to 1000 µg weekly. At 2.5 mg/ml concentration, 250 µg = 0.1 ml = 10 IU on an insulin syringe.

Combination tips, Frequently combined peptides

Melanotan II is typically used alone in the research literature (particularly for studying the melanocortin system), but some combinations appear in exploratory protocols.

PT-141 (Bremelanotide), selective alternative

This is an alternative, not a combination. PT-141 is the MC4R-selective derivative of Melanotan II, has a stronger effect on sexual function, but has no effect on pigmentation. For research focused only on the sexual pathway, PT-141 is the cleaner molecule without cutaneous side effects.

Melanotan I (Afamelanotide), cutaneous indications

Linear α-MSH analog with a primary effect on MC1R and pigmentation, without strong MC4R effects. For cosmetic tanning protocols, Afamelanotide is potentially safer (no sexual side effects, less nausea), but it is more expensive. Melanotan I is available as the approved drug Scenesse for erythropoietic protoporphyria; research peptide versions are an alternative.

GHK-Cu, complement for cutaneous protocols

For research in skin regeneration, Melanotan II is combined with GHK-Cu. Melanotan II affects pigmentation, GHK-Cu acts on collagen and epidermal regeneration. Complementary mechanisms. In the cosmetic research context, this combination is described for dermatological regeneration after UV damage.

BPC-157, anti-inflammatory component

Melanotan II may paradoxically increase sebum production via MC5R and in some subjects worsen acne. BPC-157 has an anti-inflammatory profile and in combination may mitigate dermatological side effects. Speculative, but appears in anecdotal research protocols.

Semaglutide or Tirzepatide, metabolic complement

Melanotan II suppresses appetite via MC4R. GLP-1 agonists suppress appetite via GLP-1R. Two independent mechanisms of appetite suppression, in a hypothetical research context, the combination could be supra-additive. Clinical data for this combination do not exist and the combination could lead to severe anorexia, requires caution.

Key scientific figures and citations

“Melanotan-II is a cyclic heptapeptide analog of α-MSH that is a potent agonist at melanocortin receptors and produces tanning, appetite suppression, and erectile responses in animal and human studies.”
Dorr RT. et al. (1996), Life Sci 58(20), PubMed 8637720

Statistics from preclinical literature

• Melanotan II (MT-II), a cyclic heptapeptide, sequence Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2 with an Asp-Lys lactam bridge, molecular weight 1024.18 Da
• Developed in the group of Victor J. Hruby and Mac Hadley (University of Arizona, USA) in 1987–1989
• Original development program Competitive Technologies → Palatin Technologies, later spun off into PT-141 (bremelanotide)
• Target: non-selective agonist of MC1R, MC3R, MC4R, MC5R (more potent than α-MSH, longer half-life)
• Standard experimental dose in human tanning studies: 0.025 mg/kg subcutaneously (Dorr 1996)
• In Dorr 1996 (n=10): increase in skin melanin density measured by colorimetry by ~25 % after a 10-day course
• Main adverse effects in the preclinical literature: nausea, flushing, hyperpigmentation (including atypical nevi), priapism
• Approximately 100+ publications in PubMed; development halted at Phase 2 in the late 1990s due to safety profile

Reference sources (PubMed)

1. Dorr RT. et al. (1996). “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life Sci 58(20):1777–1784. PubMed 8637720
2. Hadley ME., Dorr RT. (2006). “Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.” Peptides 27(4):921–930. PubMed 16412534
3. Wessells H. et al. (2000). “Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction.” Urology 56(4):641–646. PubMed 11018622

Regulatory status: Melanotan II is not an approved human medicinal product in any regulatory zone (FDA, EMA, ŠÚKL). The original developer’s program was discontinued; its derivative PT-141 (Bremelanotide) was FDA approved in 2019 as Vyleesi (HSDD in women). MT-II has been the subject of repeated public regulator warnings (TGA, MHRA, FDA, EMA) over illegal sales and risks. The product is sold strictly for laboratory scientific research (RUO).

Frequently asked questions about Melanotan II

These questions address the most common research-context searches about Melanotan II. For full technical documentation see the sections above.

What is Melanotan II and what is it used for in research?

Melanotan II (sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂) is a synthetic cyclic analogue of α-MSH (α-melanocyte-stimulating hormone) developed at the University of Arizona in the 1980s. In research it activates melanocortin receptors MC1R (pigmentation), MC3R/MC4R (appetite, libido). It is studied in animal models of UV-damage protection and sexual dysfunction.

What dose of Melanotan II do scientists use in animal models?

Experimental doses in animal studies: 0.025 to 0.1 mg/kg subcutaneously, often with a loading phase (daily for 1 week) and maintenance phase (twice weekly). Higher doses correlate with increased GI side effects (nausea, flushing).

What is the difference between Melanotan II and PT-141?

Melanotan II is a non-selective pan-melanocortin agonist (MC1R+MC3R+MC4R+MC5R), whereas PT-141 (Bremelanotide) is more selective for MC3R/MC4R with minimal MC1R activity. Melanotan II induces skin pigmentation, PT-141 does not. PT-141 is FDA-approved (Vyleesi 2019) for hypoactive sexual desire disorder in women.

Is Melanotan II an approved medicine or research substance?

Melanotan II is not an approved human medicine in any regulatory zone (FDA, EMA, ŠÚKL). EMA and FDA have repeatedly warned about unregulated sales. Product is sold strictly for laboratory scientific research (RUO), not for skin pigmentation or other human use.

How is Melanotan II stored and reconstituted?

Lyophilised Melanotan II should be stored at −20 °C protected from light, stability 2 to 3 years; at 2 to 8 °C 12 months. Reconstitute with bacteriostatic water slowly along the vial wall, the solution is stable 28 days at 2 to 8 °C. Standard reconstitution: 1 ml BAC water per 10 mg vial.

What is the half-life of Melanotan II and how often is it administered in studies?

Melanotan II has a longer half-life than native α-MSH (~30 minutes in plasma), but the biological pigmentation effect persists for days due to activation of melanogenesis in melanocytes. In experimental protocols it is administered daily during the loading phase, then twice weekly maintenance.

Where to buy Melanotan II in the EU for scientific research?

Melanotan II for scientific research in the EU is offered by Molequa® with FedEx delivery in 1 to 3 business days across Slovakia, Czechia and the EU. The product ships lyophilised with a Certificate of Analysis (COA), HPLC purity ≥ 99 %. Product is strictly for laboratory scientific research (RUO).